HK Stock Connect Daily Report: MICOT PHARMA-B Rises 15.19% on Phase III Ethics Approval for MT200605 - 20261106

I. Market Overview

On November 6, 2026, the three major Hong Kong indices opened lower across the board and traded below the previous close throughout the session, failing to fill the opening gap, then recovered from the intraday low in late trade but still closed lower. The Hang Seng Index closed at 24,481.86, down 1.27%; the Hang Seng TECH Index closed at 4,078.23, down 1.83%; and the Hang Seng China Enterprises Index closed at 8,274.10, down 1.13%. Full-day turnover on the Hang Seng Index reached HKD 247.4 billion, notably below HKD 356.7 billion a day earlier.

On the board, among Stock Connect constituent stocks, MICOT PHARMA-B rose 15.19%, 160 HEALTH rose 12.96%, BRETON rose 10.16%, FAMEGLOW rose 7.45% and ROBOSENSE rose 6.46%; on the downside, GALAXIS TECH fell 43.79%, KINWONG fell 15.92%, FIT HON TENG fell 14.16%, XIZHI TECH-P fell 13.03% and TIME INTERCON fell 13.01%. Pharmaceutical and utility names, which carry high dividend yields, advanced against the trend, while PCB, optical communication and connector names lagged. Across the Stock Connect universe, 147 stocks rose, 495 fell and 24 were unchanged.

Southbound capital recorded net buying of HK$2.415 billion on the day, comprising net buying of HK$3.908 billion via Stock Connect (Shanghai) and net selling of HK$1.493 billion via Stock Connect (Shenzhen), with the two legs moving in opposite directions.

II. HK Stock Connect Stock Rankings

2.1 HK Stock Connect Stock Gainers and Decliners

Source: Wind, HKEX. The content of this article is for the objective presentation of data only and does not constitute any investment advice, nor does it represent a recommendation for or value judgment on any security. The market involves risks; investment requires caution.

2.2 HK Stock Connect Active Stocks (ranked by southbound turnover)

Source: Wind, HKEX. The content of this article is for the objective presentation of data only and does not constitute any investment advice, nor does it represent a recommendation for or value judgment on any security. The market involves risks; investment requires caution.

III. HK Stock Connect-related A-share ETF Rankings

3.1 HK Stock Connect-related A-share ETF Gainers and Decliners

Source: Wind. The content of this article is for the objective presentation of data only and does not constitute any investment advice, nor does it represent a recommendation for or value judgment on any security. The market involves risks; investment requires caution.

3.2 HK Stock Connect-related A-share ETF Active Rankings (ranked by turnover)

Source: Wind. The content of this article is for the objective presentation of data only and does not constitute any investment advice, nor does it represent a recommendation for or value judgment on any security. The market involves risks; investment requires caution.

IV. Industry and Corporate Updates

1. Southbound Net Buying Reaches HK$2.415 Billion as TENCENT Leads with HK$760 Million

On November 6, southbound capital recorded net buying of HK$2.415 billion, comprising net buying of HK$3.908 billion via Stock Connect (Shanghai) and net selling of HK$1.493 billion via Stock Connect (Shenzhen), with the two legs moving in opposite directions. By stock, TENCENT (00700.HK) led with HK$760 million of net buying, followed by MEITUAN-W (03690.HK) at HK$656 million, BABA-W (09988.HK) at HK$596 million, HUA HONG GRACE (01347.HK) at HK$377 million and SMIC (00981.HK) at HK$12 million. On the sell side, XIAOMI-W (01810.HK) saw HK$1.224 billion of net selling, YOFC (06869.HK) HK$770 million and KB LAMINATES (01888.HK) HK$726 million. No broad-based Hong Kong ETF appeared in the top ten by southbound turnover.

2. MICOT PHARMA-B Jumps 15.19% to Top the Gainers on Phase III Ethics Approval for MT200605

On the evening of November 4, MICOT PHARMA-B (02335.HK) published a voluntary announcement that it is jointly undertaking a research project on its key product MT200605 with Beijing Tiantan Hospital under the National Science and Technology Major Project for major new drug development, and has received the first tranche of central government funding of RMB 960,000, with the remainder to be disbursed in stages subject to milestones. The company also obtained ethics committee approval from the lead site, Beijing Tiantan Hospital, for a Phase III clinical trial of MT200605 in patients with acute ischaemic stroke; the trial is a multi-centre, randomised, double-blind, placebo-controlled study under protocol MT200605-AIS-3041. Under the arrangement, MICOT handles R&D, manufacturing, supply, quality control and pharmacovigilance, while Beijing Tiantan Hospital leads the academic design and multi-centre coordination. On November 6, the stock rose 15.19% to HK$18.81 on turnover of HK$233 million.

3. PCB, Optical Communication and Connector Names Lead Declines as GALAXIS TECH Falls 43.79%

On November 6, AI hardware names among Stock Connect constituents led the declines. KINWONG (03228.HK) fell 15.92% to HK$44.10 on turnover of HK$186 million; FIT HON TENG (06088.HK) fell 14.16% to HK$2.91; XIZHI TECH-P (01879.HK) fell 13.03% to HK$138.80; TIME INTERCON (01729.HK) fell 13.01% to HK$9.96 on HK$366 million of turnover; and CIG (06166.HK) fell 12.67% to HK$52.05 on HK$780 million of turnover. GALAXIS TECH (02729.HK) posted the largest decline, falling 43.79% to HK$9.50 on HK$40 million of turnover.

4. Pharmaceutical and High-Dividend Names Advance as Low-Volatility Dividend ETFs Sweep the Top Five

On November 6, pharmaceutical and high-dividend names among Stock Connect constituents advanced against the trend. 160 HEALTH (02656.HK) rose 12.96% to HK$3.53 on turnover of HK$563 million; BRETON (01333.HK) rose 10.16% to HK$18.22; FAMEGLOW (03774.HK) rose 7.45% to HK$30.58; and ROBOSENSE (02498.HK) rose 6.46% to HK$15.00 on HK$180 million of turnover. Among ETFs, the Hwabao S&P HK Equities Low Volatility Dividend ETF (159220) rose 0.85%, the JPMorgan S&P HK Equities Low Volatility Dividend ETF (513630) rose 0.69%, the Yinhua product (520610) rose 0.63%, the E Fund CSI HK Equities Interior Finance ETF (159091) rose 0.45% and the ICBCCS CSI HK Equities High Dividend Selected ETF (159691) rose 0.42%, with dividend and financial theme products taking all of the top five places.

5. China-Korea Semiconductor ETF Falls 6.50% on RMB 12.125 Billion of Turnover as Japan and Biotech Products Lead Declines

On November 6, Stock Connect-related ETFs fell broadly. The Huatai-PB China Securities Han Stock Exchange China Korea Semiconductor ETF(QDII) (513310) fell 6.50% on RMB 12.125 billion of turnover and a turnover rate of 125.40%, topping the turnover list; the GF CSI HK Innovative Drugs Industry ETF(QDII) (513120) fell 1.90% on RMB 9.657 billion, ranking second; the ChinaAMC Hang Seng Technology ETF(QDII) (513180) fell 1.35% on RMB 3.480 billion; and the E Fund CSI Overseas China Internet 50 ETF (513050) fell 1.72% on RMB 2.940 billion. On the decliner side, the Harvest S&P Biotechnology Select Industry ETF(QDII) (159502) fell 6.35%, the China Universal Nasdaq Biotechnology ETF(QDII) (513290) fell 5.78%, the China Southern TOPIX ETF(QDII) (513800) fell 5.46% and the Huaan MAXIS NKY ETF(QDII) (513880) fell 4.92%.